An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)

Trial Profile

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 04 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jul 2017 Planned number of patients changed from 16 to 24.
    • 10 Jul 2017 Planned End Date changed from 31 Mar 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top